Good morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating, because that oh-so-familiar routine of meetings, deadlines, and what-not has returned. You knew this would happen, yes? So please join us as we prepare with a few cups of stimulation — our choice today is apple cider donut — and remember, no prescription is required. Meanwhile, here are some items of interest to help you along. Hope your day is smashing and, as always, do keep in touch …

Novartis (NVS) offered $3.9 billion in cash for Advanced Accelerator Applications (AAAP), providing a platform in radiopharmaceuticals that treat tumors. Last August, European regulators approved a ground-breaking, gene-modifying leukemia treatment developed by AAA, which hopes to win approval from the U.S. Food and Drug Administration in early 2018. Two years ago, Novartis purchased the GlaxoSmithKline (GSK) commercial cancer portfolio.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy